These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21843575)

  • 21. Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).
    Lee EY; Park JY; Kim DR; Song M; Sahastrabuddhe S; Kim H; Chon Y; Yang JS
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008171. PubMed ID: 32203521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
    Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
    PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
    Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
    Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Vi conjugate - a new generation of typhoid vaccine.
    Szu SC
    Expert Rev Vaccines; 2013 Nov; 12(11):1273-86. PubMed ID: 24156285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
    Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
    Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.
    Staats HF; Kirwan SM; Whisnant CC; Stephenson JL; Wagener DK; Majumder PP
    Clin Vaccine Immunol; 2010 Mar; 17(3):412-9. PubMed ID: 20107010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
    Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
    Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcutaneous Vaccination with Conjugate Typhoid Vaccine Vi-DT Induces Systemic, Mucosal, and Memory Anti-Polysaccharide Responses.
    Bhuiyan MS; Kalsy A; Arifuzzaman M; Charles RC; Harris JB; Calderwood SB; Qadri F; Ryan ET
    Am J Trop Med Hyg; 2020 Sep; 103(3):1032-1038. PubMed ID: 32720632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
    Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
    Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide.
    Bartoloni A; Norelli F; Ceccarini C; Rappuoli R; Costantino P
    Vaccine; 1995 Apr; 13(5):463-70. PubMed ID: 7543714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model.
    Mawas F; Newman G; Burns S; Corbel MJ
    J Infect Dis; 2005 Jan; 191(1):58-64. PubMed ID: 15593004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
    Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
    PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
    Gupta RK; Anderson R; Cecchini D; Rost B; Xu J; Gendreau K; Saroff DL; Marchant C; Siber GR
    Biologicals; 1999 Jun; 27(2):167-76. PubMed ID: 10600208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experimental study of controlled release microencapsulated Salmonella typhi capsular polysaccharide vaccines immunized mice].
    Yang C; Yan R; Zeng W; Zhang Y; Jia W; Liu J; Zhou S; Li X; Deng X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Dec; 20(4):626-9. PubMed ID: 14716862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
    Pulickal AS; Pollard AJ
    Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates.
    Carmenate T; Canaán L; Alvarez A; Delgado M; González S; Menéndez T; Rodés L; Guillén G
    FEMS Immunol Med Microbiol; 2004 Apr; 40(3):193-9. PubMed ID: 15039094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid.
    Pecetta S; Tontini M; Faenzi E; Cioncada R; Proietti D; Seubert A; Nuti S; Berti F; Romano MR
    Vaccine; 2016 Apr; 34(20):2334-41. PubMed ID: 27015733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.